Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s707. https://doi.org/10.25251/fpf9fe87